Antiviral drug development presents a unique set of challenges. First, viruses are constantly mutating, and drug-resistant viruses emerge easily. Therefore, combination therapies are typically required to maintain a sustained virologic response. In addition, successful treatment requires high medication adherence, which is often a challenge for patients with chronic viral infections such as hepatitis or HIV. […]Read More
Author: Suzanne Minton, Bill Poland
Dr. Suzanne Minton is the scientific communications manager at Certara. She helps develop the science-focused, value-oriented content that our customers go wild for. When she's not writing about the hottest problems in drug development, Suzanne enjoys spending time with her husband and two young children. Dr. Poland has provided pharmaceutical companies guidance in drug development decisions through scientific and decision-analytic modeling and simulation since he joined Certara in 1998. In over 40 projects for top pharmaceutical companies, he has advised on trial and program design for HCV, HIV, and other therapeutic areas, using integrated treatment adherence, pharmacokinetic, pharmacodynamic, and trial models. Recommendations included go/no-go, doses and regimens, arm sizes, and target populations. In central nervous system diseases, he has used simulations to develop flexible strategies for optimal Phase 2-3 development of multiple drugs with overlapping indications, incorporating market models to value outcomes. In oncology, he has performed and reported population exposure-efficacy and exposure-tolerability analyses for regulatory submissions. Poland’s research interests include practical viral dynamics modeling, portfolio optimization, and Bayesian adaptive program design trading off efficacy and side effects, for which he is co-author of a patent submission. Before joining Certara, he performed decision analyses for pharmaceutical and other industries at Strategic Decisions Group. He received his Ph.D. in Engineering-Economic Systems from Stanford University in 1994. He has an M.S. from the same department, an M.S. in Operations Research from the University of California at Berkeley, and a B.S. in Engineering and Applied Sciences from Harvard University.